Health Care & Life Sciences » Pharmaceuticals | Nippon Shinyaku Co. Ltd.

Nippon Shinyaku Co. Ltd. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
21,496
22,640
28,061
39,438
32,886
42,138
Total Accounts Receivable
34,137
35,010
35,135
36,878
40,164
46,555
Inventories
15,732
19,657
18,927
18,574
20,345
19,371
Other Current Assets
3,318
3,115
3,278
3,897
4,554
2,651
Total Current Assets
74,683
80,422
85,401
98,787
97,953
110,720
Net Property, Plant & Equipment
15,670
15,393
17,624
20,043
21,102
20,575
Total Investments and Advances
16,060
22,078
21,497
21,681
26,309
23,460
Intangible Assets
561
458
501
494
484
412
Other Assets
11,154
11,349
10,292
9,842
12,297
11,262
Total Assets
118,188
129,757
135,370
150,905
158,192
168,763
ST Debt & Current Portion LT Debt
280
291
302
270
257
Accounts Payable
6,099
7,118
6,759
6,232
8,639
Income Tax Payable
1,537
2,161
1,929
3,892
2,115
Other Current Liabilities
7,341
8,200
11,579
16,607
11,443
Total Current Liabilities
15,257
17,770
20,569
27,001
22,454
Long-Term Debt
1
20
12
8
5
Provision for Risks & Charges
8,857
7,997
10,410
8,064
7,422
Deferred Taxes
450
2,229
1,137
1,066
2,260
Other Liabilities
377
477
425
393
316
Total Liabilities
25,002
28,550
32,608
36,587
32,502
Common Equity (Total)
92,982
100,999
102,549
114,090
125,452
Total Shareholders' Equity
92,982
100,999
102,549
114,090
125,452
Total Equity
93,186
101,207
102,762
114,316
125,689
Liabilities & Shareholders' Equity
118,188
129,757
135,370
150,903
158,191
Accumulated Minority Interest
204
208
213
226
237

About Nippon Shinyaku Co.

View Profile
Address
14 Nishinosho-Monguchi-cho
Kyoto Kyoto 601
Japan
Employees -
Website http://www.nippon-shinyaku.co.jp
Updated 07/08/2019
Nippon Shinyaku Co., Ltd. engages in the manufacture and sale of pharmaceuticals and foodstuffs. Its operations are carried out through the following segments: Pharmaceuticals and Functional Food. The Pharmaceuticals segment develops and distributes drugs that treat urological diseases, inflammation, allergies, hematological malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders.